Clinical Trial Manager II

About Summit:

Summit Therapeutics Inc. is a biopharmaceutical oncology company with a mission focused on improving quality of life, increasing potential duration of life, and resolving serious unmet medical needs. At Summit, we believe in building a team of world class professionals who are passionate about this mission, and it is our people who drive this mission to reality. Summit’s core values include integrity, passion for excellence, purposeful urgency, collaboration, and our commitment to people.

Our employees are truly the heart and soul of our culture, and they are invaluable in shaping our journey toward excellence.

Summit’s team is inspired to touch and help change lives through Summit’s clinical studies in the field of oncology. Summit has multiple global Phase 3 clinical studies, including:

Non-small Cell Lung Cancer (NSCLC)

• HARMONi:
  Phase 3 clinical study which was intended to evaluate ivonescimab combined with chemotherapy compared to placebo plus chemotherapy in patients with EGFR-mutated, locally advanced or metastatic non-squamous NSCLC who were previously treated with a 3rd generation EGFR TKI.
• HARMONi-3:
  Phase 3 clinical study which is intended to evaluate ivonescimab combined with chemotherapy compared to pembrolizumab combined with chemotherapy in patients with first-line metastatic NSCLC.
• HARMONi-7:
  Phase 3 clinical study which is intended to evaluate ivonescimab monotherapy compared to pembrolizumab monotherapy in patients with first-line metastatic NSCLC.

Colorectal Cancer (CRC)

• HARMONi-GI3:
  Phase 3 clinical study intended to evaluate ivonescimab in combination with chemotherapy compared with bevacizumab plus chemotherapy.

Ivonescimab is an investigational therapy not presently approved by any regulatory authority other than China’s National Medical Products Administration (NMPA). Summit is headquartered in Miami, Florida, and has additional offices in California, New Jersey, the UK, and Ireland.

Overview of Role:

The Clinical Trial Manager 2 (CTM2) is an experienced clinical operations professional accountable for all aspects of Clinical Trial Management for global studies. The CTM2 is accountable for study start up and maintenance through study close out, coordinates, leads and drives deliverables for assigned sites, countries, or regions for one or more studies or programs simultaneously. The CTM2s are also accountable for site, country, or region performance metrics and quality of deliverables in the clinical trial.

• Oversee site selection, feasibility, activation, enrollment, monitoring, issue escalation, and closeout activities.
• Partners with the CRO to ensure robust clinical trial execution, data monitoring strategies, and patient enrollment strategies.
• Drafts, reviews and manages study related plans, processes including Informed Consent Forms, Investigator agreements (CTA), CRFs, CRF guidelines, statistical/pharmacokinetic analysis plans, monitoring plan, data management, and safety monitoring as delegated.
• Reviews and approves essential document packages.
• Tracks and ensures resolution of Risk Based Quality Management actions and signals.
• Conducts sponsor oversight of CRO monitoring activities by reviewing all types of monitoring reports; monitors site performance, identifies quality trends, and ensures timely resolution of monitoring findings and action items.
• Performs quality oversight visits.
• Reviews clinical data listings, reports and dashboards ensuring data currency and completeness inclusive of laboratory, imaging and other protocol required assessments.
• Identifies trends and follows up on outstanding data issues with CRO and Study team.
• Responsible for oversight on the maintenance and completeness of the TMF, performing periodic quality…